CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Neurobiology of Aging

• Publication date

  2013-03-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.neurobiolaging.2012.06.005PMID 22763024
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?

  2010cited by this paper
• Neuroinflammatory processes in Alzheimer’s disease

  2010cited by this paper
• Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex.

  2010cited by this paper
• The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages.

  2009cited by this paper
• Involvement of an Altered 5-HT6 Receptor Function in Behavioral Symptoms of Alzheimer's Disease

  2008cited by this paper
• Comparison Analysis of Gene Expression Patterns between Sporadic Alzheimer's and Parkinson's Disease

  2007cited by this paper
• Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.

  2007cited by this paper
• Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease.

  2006cited by this paper
• Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation

  2005cited by this paper
• Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains

  2003cited by this paper
• The Human Brain Revisited: Opportunities and Challenges in Postmortem Studies of Psychiatric Disorders

  2002cited by this paper
• Psychosis of Alzheimer’s disease is associated with elevated muscarinic M2 binding in the cortex

  2001cited by this paper
• The Present Behavioural Examination (PBE): the development of an interview to measure current behavioural abnormalities

  1992cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper

• Efficacy and Safety of Cannabinoids for Neuropsychiatric Symptoms of Dementia: A Systematic Review with Meta-analysis.

  2026cites this paper
• Identifying a combination of biomarkers to predict treatment response to nabilone for agitation in Alzheimer's disease - an exploratory post hoc analysis.

  2025cites this paper
• Cannabinoid Receptor 2 (CB2R) as potential target for the pharmacological treatment of neurodegenerative diseases.

  2025cites this paper
• The Interplay Between CB2 and NMDA Receptors in Parkinson’s Disease

  2025cites this paper
• Targeting GPR55 with Cannabidiol Derivatives: A Molecular Docking Approach Toward Novel Neurotherapeutics

  2025cites this paper
• Cannabidiol prevents cognitive and social deficits in a male rat model of Alzheimer’s disease through CB1 activation and inflammation modulation

  2025cites this paper
• Perinatal Ethanol Exposure Induces Astrogliosis and Decreases GRP55/PEA-Mediated Neuroprotection in Hippocampal Astrocytes of the 3×Tg Alzheimer’s Animal Model

  2025cites this paper
• A randomized clinical trial of low-dose cannabis extract in Alzheimer's disease

  2025cites this paper
• A Holistic Review of Cannabis and Its Potential Risks and Benefits in Mental Health

  2025cites this paper
• Multi-Target Protective Effects of β-Caryophyllene (BCP) at the Intersection of Neuroinflammation and Neurodegeneration

  2025cites this paper
• Recent Preclinical Evidence on Phytocannabinoids in Neurodegenerative Disorders: A Focus on Parkinson’s and Alzheimer’s Disease

  2025cites this paper
• Mechanisms of the Pathogenesis of Alzheimer’s Disease: The Role of the Basal Forebrain

  2025cites this paper
• Neuroprotective effects of G9a inhibition and cannabinoid receptor activation in Alzheimer's disease through a pharmacological approach

  2025cites this paper
• Calcium (Ca2+) hemostasis, mitochondria, autophagy, and mitophagy contribute to Alzheimer's disease as early moderators

  2024cites this paper
• Endocannabinoid system alterations in Alzheimer's disease: A mini-review

  2024cites this paper
• Potential of CBD Acting on Cannabinoid Receptors CB1 and CB2 in Ischemic Stroke

  2024cites this paper
• New insights into butyrylcholinesterase: Pharmaceutical applications, selective inhibitors and multitarget-directed ligands.

  2024cites this paper
• Arachidonic acid in aging: New roles for old players

  2024cites this paper
• Beta-Caryophyllene, a Cannabinoid Receptor Type 2 Selective Agonist, in Emotional and Cognitive Disorders

  2024cites this paper
• Explicit and implicit effects of gaming content on social media on the behavior of young adults

  2024cites this paper
• Cannabinoids for Cancer-related Pain Management: An Update on Therapeutic Applications and Future Perspectives

  2024cites this paper
• Cannabinoids: Role in Neurological Diseases and Psychiatric Disorders

  2024cites this paper
• Inflammaging and Immunosenescence in the Post‐COVID Era: Small Molecules, Big Challenges

  2024cites this paper
• The role of the basal forebrain in the pathogenesis of Alzheimer’s disease

  2024cites this paper
• Microglial cannabinoid receptor type II stimulation improves cognitive impairment and neuroinflammation in Alzheimer’s disease mice by controlling astrocyte activation

  2024influential citation
• Cognitive improvement via cortical cannabinoid receptors and choline‐containing lipids

  2024cites this paper
• Unveiling the Potential of Phytocannabinoids: Exploring Marijuana’s Lesser-Known Constituents for Neurological Disorders

  2024cites this paper
• The Endocannabinoid System in Alzheimer's Disease: A Network Meta‐Analysis

  2024influential citation
• Cannabinoid type 2 receptor deficiency leads to Aβ-induced cognitive impairment through promoting microglial sensitivity to Aβ in the prefrontal cortex in mice

  2024cites this paper
• Phytocannabinoids—Evaluation of their therapeutic role in neuroinflammation

  2024cites this paper
• Neurolipid systems: A new target for the treatment of dementia

  2024cites this paper
• Cannabidiol and Alzheimer's disease.

  2024cites this paper
• Interplay among Oxidative Stress, Autophagy, and the Endocannabinoid System in Neurodegenerative Diseases: Role of the Nrf2- p62/SQSTM1 Pathway and Nutraceutical Activation

  2024cites this paper
• Targeting Neuroinflammation as Disease Modifying Approach to Alzheimer's Disease: Potential and Challenges.

  2023cites this paper
• Exploring the therapeutic potential of natural compounds modulating the endocannabinoid system in various diseases and disorders: review

  2023cites this paper
• Neuroinflammation in the Central Nervous System: Exploring the Evolving Influence of Endocannabinoid System

  2023cites this paper
• Cannabinoids in Medicine: A Multifaceted Exploration of Types, Therapeutic Applications, and Emerging Opportunities in Neurodegenerative Diseases and Cancer Therapy

  2023cites this paper
• An enquiry to the role of CB1 receptors in neurodegeneration.

  2023cites this paper
• Under the umbrella of depression and Alzheimer's disease physiopathology: can cannabinoids be a dual-pleiotropic therapy?

  2023cites this paper
• The current role of cannabis and cannabinoids in health: A comprehensive review of their therapeutic potential.

  2023cites this paper
• The Expression of the Endocannabinoid Receptors CB2 and GPR55 Is Highly Increased during the Progression of Alzheimer’s Disease in AppNL-G-F Knock-In Mice

  2023cites this paper
• Alcohol as a Modifiable Risk Factor for Alzheimer’s Disease—Evidence from Experimental Studies

  2023cites this paper
• Recent Development in the Understanding of Molecular and Cellular Mechanisms Underlying the Etiopathogenesis of Alzheimer’s Disease

  2023cites this paper
• First-in-human imaging using [^11C]MDTC: a radiotracer targeting the cannabinoid receptor type 2

  2023cites this paper
• Regulatory role of the endocannabinoid system on glial cells toward cognitive function in Alzheimer’s disease: A systematic review and meta-analysis of animal studies

  2023cites this paper
• Cannabinoids in neuroinflammatory disorders: Focusing on multiple sclerosis, Parkinsons, and Alzheimers diseases

  2023cites this paper
• Therapeutic properties of multi-cannabinoid treatment strategies for Alzheimer’s disease

  2022cites this paper
• The impact of phyto- and endo-cannabinoids on central nervous system diseases：A review

  2022cites this paper
• Recent Advances on Type-2 Cannabinoid (CB2) Receptor Agonists and Their Therapeutic Potential.

  2022cites this paper
• The synaptic lipidome in health and disease.

  2022cites this paper
• Cannabinoid Receptors and Glial Response Following a Basal Forebrain Cholinergic Lesion

  2022cites this paper
• Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders

  2022cites this paper
• Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice

  2022cites this paper
• Medicinal Cannabis and Central Nervous System Disorders

  2022cites this paper
• Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders

  2022cites this paper
• Microglial Endocannabinoid Signalling in AD

  2022cites this paper
• Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells

  2022cites this paper
• Gene Expression Analysis of the Endocannabinoid System in Presymptomatic APP/PS1 Mice

  2022cites this paper
• The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation

  2022cites this paper
• Impact of the Cannabinoid System in Alzheimer's Disease

  2022cites this paper
• New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders

  2022cites this paper
• Revealing genomic changes responsible for cannabinoid receptor loss in parrots: mechanism and functional effects

  2022cites this paper
• Transcriptomic Profiling in Mice With CB1 receptor Deletion in Primary Sensory Neurons Suggests New Analgesic Targets for Neuropathic Pain

  2022cites this paper
• Alzheimer's disease is an inherent, natural part of human brain aging: an integrated perspective.

  2022cites this paper
• Cannabinoid receptor 2 evolutionary gene loss makes parrots more susceptible to neuroinflammation

  2022cites this paper
• Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential

  2022cites this paper
• Endocannabinoid System Biomarkers in Alzheimer's Disease

  2022cites this paper
• Hypothesis on ontogenesis and pathophysiology of Alzheimer’s disease

  2022cites this paper
• Antagonization of OX1 Receptor Potentiates CB2 Receptor Function in Microglia from APPSw/Ind Mice Model

  2022cites this paper
• Intracellular Molecular Targets and Signaling Pathways Involved in Antioxidative and Neuroprotective Effects of Cannabinoids in Neurodegenerative Conditions

  2022cites this paper
• The cannabinoid system and microglia in health and disease.

  2021cites this paper
• Understanding the Modulatory Effects of Cannabidiol on Alzheimer’s Disease

  2021cites this paper
• Cannabinoid receptor 2 selective agonists and Alzheimer's disease: An insight into the therapeutic potentials

  2021cites this paper
• The Endocannabinoid System and Its Therapeutic Potential

  2021influential citation
• The Neuroprotective properties, Functions and Roles of Cannabis sativa in selected diseases related to the Nervous System.

  2021cites this paper
• The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease?

  2021cites this paper
• A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of β-caryophyllene, a dietary cannabinoid.

  2021cites this paper
• Cannabinoids for Agitation in Alzheimer's Disease.

  2021cites this paper
• The Effects and Mechanisms of Phytochemicals on Alzheimer’s Disease Neuropathology

  2021cites this paper
• Untapped endocannabinoid pharmacological targets: pipe dream or pipeline?

  2021cites this paper
• Cannabinoid Receptors and Ligands: Lessons from CNS Disorders and the Quest for Novel Treatment Venues.

  2021cites this paper
• The role of fatty acid amide hydrolase enzyme inhibitors in Alzheimer's disease

  2021cites this paper
• Orchestration of the circadian clock and its association with Alzheimer's disease: role of endocannabinoid signaling.

  2021cites this paper
• TIBBİ KENEVİR VE SAĞLIK: FARMAKOLOJİK BİR DERLEME

  2021cites this paper
• Interplay Between Endocannabinoid System and Neurodegeneration: Focus on Polypharmacology.

  2021cites this paper
• Dementia: Alzheimer’s Disease

  2021cites this paper
• Cannabinoids as anticancer and neuroprotective drugs: Structural insights and pharmacological interactions—A review

  2021cites this paper
• Effects of CB2 Receptor Agonist JWH133 on Aβ42-Induced Hippocampal Neurons

  2020cites this paper
• Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson’s Disease

  2020cites this paper
• Crosstalk between the M1 muscarinic acetylcholine receptor and the endocannabinoid system: A relevance for Alzheimer's disease?

  2020cites this paper
• Adolescent binge‐ethanol accelerates cognitive impairment and β‐amyloid production and dysregulates endocannabinoid signaling in the hippocampus of APP/PSE mice

  2020cites this paper
• Endocannabinoid Receptors in the CNS: Potential Drug Targets for the Prevention and Treatment of Neurologic and Psychiatric Disorders

  2020cites this paper
• Functionalized Cannabinoid Subtype 2 Receptor Ligands: Fluorescent, PET, Photochromic and Covalent Molecular Probes

  2020cites this paper
• Cannabis, the Endocannabinoid System and Immunity—the Journey from the Bedside to the Bench and Back

  2020cites this paper
• Emerging Promise of Cannabinoids for the Management of Pain and Associated Neuropathological Alterations in Alzheimer’s Disease

  2020influential citation
• Endocannabinoid system alterations in Alzheimer's disease: a systematic review of human studies.

  2020cites this paper
• The impact of cannabinoid type 2 receptors (CB2Rs) in neuroprotection against neurological disorders

  2020cites this paper
• Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases

  2020cites this paper
• Cannabis Phytochemicals: A Review of Phytocannabinoid Chemistry and Bioactivity as Neuroprotective Agents

  2020cites this paper
• Imbalance of Endocannabinoid/Lysophosphatidylinositol Receptors Marks the Severity of Alzheimer’s Disease in a Preclinical Model: A Therapeutic Opportunity

  2020influential citation